The miR-16-1-3p suppresses proliferation and invasiveness via the MDM2-p53 axis in TGF-β1 signaling in osteosarcoma
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201249
DOI: 10.1016/j.omton.2026.201249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Wenyu Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Future Biophysics, Moscow Center for Advanced Studies, 123592 Moscow, Russia. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Russian Science Foundation, Ministry of Science and Higher Education of the Russian Federation.
Abstract (Originalsprache)
The TGF-β signaling pathway has both tumor-suppressive and metastasis-promoting effects in cancer, yet the molecular determinants governing this switch remain unclear. Here, we investigated the miR-16-1-3p/MDM2/p53 axis as a potential regulator of TGF-β/Smad signaling output in osteosarcoma. miR-16-1-3p overexpression alone markedly reduced the proliferative and clonogenic potential of U2OS cells, while its combination with TGF-β treatment strongly enhanced G1-phase arrest and nearly abolished tumor growth capacity. miR-16-1-3p inhibited TGF-β-induced actin remodeling and epithelial-mesenchymal transition (EMT)-associated changes. While TGF-β promoted both 2D and 3D migration, miR-16-1-3p overexpression, alone or combined with TGF-β, counteracted its pro-migratory effects. Mechanistically, miR-16-1-3p reduced MDM2 expression and stabilized p53, which was associated with enhanced p21 induction and suppression of proliferative responses under TGF-β stimulation. Co-administration of TGF-β and miR-16-1-3p markedly increased cisplatin sensitivity in wild-type U2OS cells and reduced tumor nodule volume, Ki67 expression, and metastasis in the chicken chorioallantoic membrane model. Collectively, these findings suggest that miR-16-1-3p biases TGF-β signaling output toward anti-growth responses, while attenuating pro-migratory effects through MDM2 inhibition and p53 stabilization, providing a mechanistic rationale for improving therapeutic responses in osteosarcoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Future Biophysics, Moscow Center for Advanced Studies, 123592 Moscow, Russia.
- Phystech School of Biological and Medical Physics, Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
- Institute of Cell Biophysics of Russian Academy of Sciences, 142290 Pushchino, Russia.
Förderung
- Russian Science Foundation
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Xue, W., Wang, Y., Smirnova, A. V., Malakhov, P. A., Pustovalova, M., Kuzmin, D. V., & Leonov, S. (2026). The miR-16-1-3p suppresses proliferation and invasiveness via the MDM2-p53 axis in TGF-β1 signaling in osteosarcoma. Molecular Therapy Oncology, 34(2), 201249. https://doi.org/10.1016/j.omton.2026.201249
Vancouver
Xue W, Wang Y, Smirnova AV, Malakhov PA, Pustovalova M, Kuzmin DV, et al. The miR-16-1-3p suppresses proliferation and invasiveness via the MDM2-p53 axis in TGF-β1 signaling in osteosarcoma. Molecular Therapy Oncology. 2026;34(2):201249. doi:10.1016/j.omton.2026.201249
BibTeX
@article{Xue2026,
author = {Xue, Wenyu and Wang, Yuzhe and Smirnova, A V and Malakhov, P A and Pustovalova, Margarita and Kuzmin, Denis V and Leonov, Sergey},
title = {The miR-16-1-3p suppresses proliferation and invasiveness via the MDM2-p53 axis in TGF-β1 signaling in osteosarcoma},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201249},
doi = {10.1016/j.omton.2026.201249}
}
EUVIMED